Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2004 3
2006 3
2009 3
2010 4
2011 3
2012 1
2013 1
2014 1
2015 1
2020 2
2021 3
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: cupini s. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Immunotherapy-induced eczema treated with dupilumab.
D'Erme AM, Fidanzi C, Mori N, Musettini G, Cupini S, Barbara C, Allegrini G, Bagnoni G, Janowska A. D'Erme AM, et al. Among authors: cupini s. J Eur Acad Dermatol Venereol. 2024 May;38(5):e447-e449. doi: 10.1111/jdv.19707. Epub 2023 Dec 12. J Eur Acad Dermatol Venereol. 2024. PMID: 38084780 No abstract available.
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Boccaccino A, Rossini D, Raimondi A, Carullo M, Lonardi S, Morano F, Santini D, Tomasello G, Niger M, Zaniboni A, Daniel F, Bustreo S, Procaccio L, Clavarezza M, Cupini S, Libertini M, Palermo F, Pietrantonio F, Cremolini C. Boccaccino A, et al. Among authors: cupini s. Eur J Cancer. 2023 Aug;189:112910. doi: 10.1016/j.ejca.2023.05.001. Epub 2023 May 6. Eur J Cancer. 2023. PMID: 37301718 Clinical Trial.
Consequences of targeted treatments for second-line therapy.
De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, Cappuzzo F. De Maio E, et al. Among authors: cupini s. Ann Oncol. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. Ann Oncol. 2010. PMID: 20943621 Free article. Review.
Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational Status.
Lessi F, Morelli M, Franceschi S, Aretini P, Menicagli M, Marranci A, Pasqualetti F, Gambacciani C, Pieri F, Grimod G, Zucchi V, Cupini S, Di Stefano AL, Santonocito OS, Mazzanti CM. Lessi F, et al. Among authors: cupini s. Int J Mol Sci. 2023 Jun 14;24(12):10147. doi: 10.3390/ijms241210147. Int J Mol Sci. 2023. PMID: 37373295 Free PMC article.
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Fanotto V, Rossini D, Casagrande M, Bergamo F, Spagnoletti A, Santini D, Antoniotti C, Cupini S, Daniel F, Nasca V, Vetere G, Zaniboni A, Borelli B, Carullo M, Conca V, Passardi A, Tamburini E, Masi G, Pella N, Cremolini C. Fanotto V, et al. Among authors: cupini s. Cancers (Basel). 2023 Nov 16;15(22):5451. doi: 10.3390/cancers15225451. Cancers (Basel). 2023. PMID: 38001711 Free PMC article.
Light-induced charge generation in polymeric nanoparticles restores vision in advanced-stage retinitis pigmentosa rats.
Francia S, Shmal D, Di Marco S, Chiaravalli G, Maya-Vetencourt JF, Mantero G, Michetti C, Cupini S, Manfredi G, DiFrancesco ML, Rocchi A, Perotto S, Attanasio M, Sacco R, Bisti S, Mete M, Pertile G, Lanzani G, Colombo E, Benfenati F. Francia S, et al. Among authors: cupini s. Nat Commun. 2022 Jun 27;13(1):3677. doi: 10.1038/s41467-022-31368-3. Nat Commun. 2022. PMID: 35760799 Free PMC article.
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Coltelli L, Allegrini G, Orlandi P, Finale C, Fontana A, Masini LC, Scalese M, Arrighi G, Barletta MT, De Maio E, Banchi M, Fini E, Guidi P, Frenzilli G, Donati S, Giovannelli S, Tanganelli L, Salvadori B, Livi L, Meattini I, Pazzagli I, Di Lieto M, Pistelli M, Casadei V, Ferro A, Cupini S, Orlandi F, Francesca D, Lorenzini G, Barellini L, Falcone A, Cosimi A, Bocci G. Coltelli L, et al. Among authors: cupini s. NPJ Breast Cancer. 2022 Mar 21;8(1):33. doi: 10.1038/s41523-022-00400-6. NPJ Breast Cancer. 2022. PMID: 35314692 Free PMC article.
32 results